null
ChEBI ID: 90628
| Member | Definition | Role |
|---|---|---|
| benzyl acetate | The acetate ester of benzyl alcohol. | benzyl acetate |
| benzyl benzoate | A benzoate ester obtained by the formal condensation of benzoic acid with benzyl alcohol. It has been isolated from the plant species of the genus Polyalthia. | benzyl benzoate |
| benzylparaben | Benzyl parahydroxybenzoate | |
| butylbenzyl phthalate | Butylbenzyl phthalate | |
| cgp 42112a | A hexapeptide consisting of L-tyrosine, L-lysine, L-histidine, L-proline and L-isoleucine amino acid residues coupled in sequence and in which the amino group of the L-tyrosyl residue is substituted by a (pyridin-3-ylcarbonyl)nitrilo group and in which the L-lysyl side chain amino group is substituted by a {N(2)-[(benzyloxy)carbonyl]-L-arginyl}nitrilo group. It is a potent angiotensin II receptor type 2 (AT2 receptor) agonist. | CGP-42112A |
| N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide | A tripeptide resulting from the formal condensation of the carboxy group of N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valine with the amino group of benzyl (2E,4S)-4-(L-leucylamino)-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate. It is an inhibitor of the main protease of SARS-CoV-2. | N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide |
| nicotinic acid benzyl ester | A benzyl ester resulting from the formal condensation of the carboxy group of nicotinic acid with benzyl alcohol. It has been used as a rubefacient. | benzyl nicotinate |
| thiobenzyl benzyloxycarbonyl-l-lysinate | An L-lysine derivative that is L-lysine in which the amino group is replaced by a [(benzyloxy)carbonyl]amino group and the carboxy group is replaced by a (benzylsulfanyl)carbonyl group. It is a substrate for a sensitive colorimetric assay for trypsin-like enzymes. | thiobenzyl benzyloxycarbonyl-L-lysinate |
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 86 (9.72) | 18.7374 |
| 1990's | 208 (23.50) | 18.2507 |
| 2000's | 239 (27.01) | 29.6817 |
| 2010's | 263 (29.72) | 24.3611 |
| 2020's | 89 (10.06) | 2.80 |
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 41 (4.26%) | 5.53% |
| Reviews | 40 (4.15%) | 6.00% |
| Case Studies | 29 (3.01%) | 4.05% |
| Observational | 5 (0.52%) | 0.25% |
| Other | 848 (88.06%) | 84.16% |